NDA 021756 · Bausch and Lomb INC
Macugen
Pegaptanib Sodium · Intravitreal
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 26, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Sep 17, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
36
9 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 17, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- MACUGEN · PEGAPTANIB SODIUM EQ 0.3MG ACID/0.09ML · INJECTABLE, INTRAVITREAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegaptanib" as an intervention, any sponsor and status, largest first.
Kagawa UniversityAcademic, hospital or other
NCT02321267 · 1,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin · For: Macular Disease
Sites: Hiragi, Japan
- A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMDStatus unknown
Eyetech PharmaceuticalsIndustry
NCT00354445 · 1,000 participants · Start Jun 2006
Drug: pegaptanib sodium (Macugen) · For: Age-Related Macular Degeneration (AMD)
Sites: Abilene, Texas
- A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.Pivotal-lookingCompleted
Eyetech PharmaceuticalsIndustry
NCT00321997 · 540 participants · Start May 2001
Drug: Pegaptanib sodium · For: Age-Related Macular Degeneration
- Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)Pivotal-lookingTerminated
Eyetech PharmaceuticalsIndustry
NCT00134667 · 360 participants · Start Mar 2005
Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin); Macugen (pegaptanib sodium) · For: Age-Related Macular Degeneration
Sites: Tucson, Arizona
PfizerPfizer (PFE)
NCT00605280 · 317 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Standard of Care; Macugen · For: Macular Edema Associated With Diabetes Mellitus
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 73 sites in all
PfizerPfizer (PFE)
NCT00327470 · 288 participants · Start Jul 2006 · Primary completion Aug 2009
Drug: Pegaptanib Sodium 0.3 mg · For: Age Related Macular Degeneration (AMD); Macular Degeneration; Choroidal Neovascularization (CNV)
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 58 sites in all
- A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)Pivotal-lookingTerminated
Eyetech PharmaceuticalsIndustry
NCT00312351 · 262 participants · Start Apr 2006
Drug: Pegaptanib sodium · For: Macular Degeneration
Sites: Charlotte, North Carolina
- A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular EdemaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01100307 · 243 participants · Start May 2010 · Primary completion Aug 2012
Drug: pegaptanib sodium · For: Macular Edema; Diabetic Mellitus; Retinal Disease
Sites: Nagoya, Japan; Akita, Japan; Aomori, Japan · 43 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM, Choi YH, Tu MJ · Pharmacol Rev 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- Age related macular degeneration.
Arnold JJ, Heriot W · BMJ Clin Evid 2007 · Systematic Review
- Pegaptanib sodium for the treatment of age-related macular degeneration.
Apte RS · Expert Opin Pharmacother 2008 · Research Support, Non-U.S. Gov't, Systematic Review
- Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study.
Rinaldi M, Chiosi F, DellʼOmo R, et al. · Retina 2013 · Clinical Trial
- Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ, Salvador I, Martí-Carvajal AJ, et al. · Cochrane Database Syst Rev 2023 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Bausch and Lomb INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.